Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 9,200 shares, a decline of 68.6% from the February 28th total of 29,300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 20,100 shares, the short-interest ratio is currently 0.5 days.
Wall Street Analyst Weigh In
Separately, UBS Group raised shares of Nanobiotix to a "hold" rating in a report on Monday, February 17th.
Read Our Latest Research Report on Nanobiotix
Nanobiotix Stock Performance
NASDAQ:NBTX traded down $0.03 during midday trading on Monday, hitting $3.58. 3,228 shares of the company traded hands, compared to its average volume of 21,525. The firm's fifty day moving average is $3.57 and its 200-day moving average is $3.83. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51.
Institutional Investors Weigh In On Nanobiotix
Several hedge funds and other institutional investors have recently made changes to their positions in NBTX. Millennium Management LLC purchased a new position in shares of Nanobiotix during the 4th quarter worth about $39,000. Jane Street Group LLC purchased a new position in shares of Nanobiotix during the fourth quarter valued at approximately $73,000. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the fourth quarter valued at approximately $29,000. Finally, OLD Mission Capital LLC purchased a new stake in shares of Nanobiotix in the fourth quarter worth approximately $139,000. Hedge funds and other institutional investors own 38.81% of the company's stock.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Articles
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
